Presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Necrotizing enterocolitis ‐ 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in necrotizing enterocolitis ‐ 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Structural outcome ‐ retinal detachment · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes structural outcome ‐ retinal detachment compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Outcomes* · preterm infants with type 1 ROP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Structural outcome ‐ retinal detachment · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy combined with… may leads to lower structural outcome ‐ retinal detachment (unit of analysis: eyes) compared with laser/cryotherapy (low certainty).
1 finding from 1 review
Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy combined with… changes local adverse effects ‐ perioperative retinal haemorrhages (unit of… compared with laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP by 55 weeks' PMA · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy combined with… may leads to lower recurrence of ROP by 55 weeks' postmenstrual age compared with laser/cryotherapy (low certainty).
1 finding from 1 review
Structural outcome ‐ complete retinal detachment (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes structural outcome ‐ complete retinal detachment (unit of analysis:… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Refractive error ‐ very high myopia ‐ at 30 months of age (unit of analysis: eyes) · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy may leads to lower refractive error ‐ very high myopia ‐ at 30 months of age (unit of… compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality before discharge from primary hospital compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Mortality at 30 months of age · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality at 30 months of age compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Local adverse effects ‐ corneal opacity requiring corneal transplant (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes local adverse effects ‐ corneal opacity requiring corneal transplant… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Local adverse effects ‐ lens opacity requiring cataract removal (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes local adverse effects ‐ lens opacity requiring cataract removal… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP (up to 6 months of age) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (up to 6 months of age) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (unit of analysis: eyes) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Mortality, near term corrected age or discharge · preterm infants
Lower showed no clear difference in mortality, near term corrected age or discharge compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm infants
Lower showed no clear difference in neurodevelopmental disability compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Intubation in the delivery room · preterm infants
Lower showed no clear difference in intubation in the delivery room compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review